Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vbi Vaccines Inc CS (VBIV)

Vbi Vaccines Inc CS (VBIV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 256,630
  • Shares Outstanding, K 258,257
  • Annual Sales, $ 630 K
  • Annual Income, $ -69,750 K
  • 60-Month Beta 2.01
  • Price/Sales 397.04
  • Price/Cash Flow N/A
  • Price/Book 1.93
Trade VBIV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings -0.08 on 05/09/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.150 on 12/12/12
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 192.98% ( -365.27%)
  • Historical Volatility 106.62%
  • IV Percentile 93%
  • IV Rank 24.37%
  • IV High 632.28% on 05/09/22
  • IV Low 51.42% on 08/10/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 17,654
  • Open Int (30-Day) 15,984

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.08
  • Prior Year -0.07
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9040 +9.92%
on 05/20/22
1.4750 -32.63%
on 04/21/22
-0.4563 (-31.47%)
since 04/20/22
3-Month
0.9040 +9.92%
on 05/20/22
1.8600 -46.58%
on 03/29/22
-0.4063 (-29.02%)
since 02/18/22
52-Week
0.9040 +9.92%
on 05/20/22
4.3100 -76.94%
on 06/29/21
-2.2063 (-68.95%)
since 05/20/21

Most Recent Stories

More News
VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that health economics and outcomes...

VBIV : 0.9937 (+2.43%)
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VBIV : 0.9937 (+2.43%)
VRDN : 13.58 (+4.38%)
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the first...

VBIV : 0.9937 (+2.43%)
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.77% and 72.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 24.72 (+4.00%)
VBIV : 0.9937 (+2.43%)
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the European Commission (EC)...

VBIV : 0.9937 (+2.43%)
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that tumor response and overall...

VBIV : 0.9937 (+2.43%)
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced updated clinical and preclinical...

VBIV : 0.9937 (+2.43%)
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbrio™ [Hepatitis B...

VBIV : 0.9937 (+2.43%)
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President...

VBIV : 0.9937 (+2.43%)
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 40.88%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

VBIV : 0.9937 (+2.43%)
VYGR : 6.36 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus...

See More

Key Turning Points

3rd Resistance Point 1.1236
2nd Resistance Point 1.0618
1st Resistance Point 1.0277
Last Price 0.9937
1st Support Level 0.9318
2nd Support Level 0.8700
3rd Support Level 0.8359

See More

52-Week High 4.3100
Fibonacci 61.8% 3.0089
Fibonacci 50% 2.6070
Fibonacci 38.2% 2.2051
Last Price 0.9937
52-Week Low 0.9040

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar